Top Markets
Coin of the day
Taysha Gene Therapies, Inc. Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA
株式のランク #6655
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and... Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
株価
$6.02
最終同期: 2026-08-27
時価総額
$1.93B
変化(1日)
0.00%
変化(1年)
112.72%
US
取引 Taysha Gene Therapies, Inc. (TSHA)

カテゴリー

Taysha Gene Therapies, Inc.(TSHA)のP/B比率
2026 時点のP/B比率 TTM: 0
Taysha Gene Therapies, Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
Taysha Gene Therapies, Inc. の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH